علاج سرطان الخلايا الحرشفية في قناة الشرج غير النقيلي بدون نقائل بعيدة

References

• Currently, concurrent chemoRT is the recommended primary treatment of patients with nonmetastatic anal canal cancer as well as for patients with positive para-aortic lymph nodes that can be included in the radiation field, although only limited retrospective data support use in this setting.
• Mitomycin/5-FU or mitomycin/capecitabine is administered concurrently with radiation.
• Alternatively, 5-FU/cisplatin can be given with concurrent radiation (category 2B).
• All patients should receive a minimum RT dose of 45 Gy to the primary cancer.
• Patients are re-evaluated using DRE between 8 and 12 weeks after completion of chemoRT.
• Following re-evaluation, patients are classified according to whether they have a complete remission of disease, persistent disease, or progressive disease.